Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

KT-621Positive

AI Analysis

Summary

Kymera Therapeutics appointed Elizabeth Laws, Ph.D., as Senior Vice President and Global Program Team Leader for KT-621, its first-in-class oral STAT6 degrader.

Importance:2/10

Sentiment:

0.30

management_appointmentKT-621STAT6_degraderoral_drug

Related Companies

$SNY

Read the original article

Published by yahoo_finance on July 7, 2026 11:00 AM

Read Original